Understanding COVID-19-related myocarditis: pathophysiology, diagnosis, and treatment strategies.

Hongyang Shu, Chunxia Zhao, Dao Wen Wang
Author Information
  1. Hongyang Shu: Division of Cardiology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology; Hubei Key Laboratory of Genetics and Molecular Mechanisms of Cardiological Disorders, Wuhan 430030, China.
  2. Chunxia Zhao: Division of Cardiology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology; Hubei Key Laboratory of Genetics and Molecular Mechanisms of Cardiological Disorders, Wuhan 430030, China.
  3. Dao Wen Wang: Division of Cardiology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology; Hubei Key Laboratory of Genetics and Molecular Mechanisms of Cardiological Disorders, Wuhan 430030, China.

Abstract

Coronavirus disease 2019 (COVID-19) disease has infected nearly 600 million people, resulting in > 6 million deaths, with many of them dying from cardiovascular diseases. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is caused by a combination of the virus surface spike protein and the human angiotensin-converting enzyme 2 (ACE2) receptor. In addition to being highly expressed in the lungs, ACE2 is widely distributed in the heart, mainly in myocardial cells and pericytes. Like other types of viruses, SARS-CoV-2 can cause myocarditis after infecting the myocardial tissue, which is attributed to the direct damage of the virus and uncontrolled inflammatory reactions. Patients with chest tightness, palpitation, abnormal electrocardiogram, and cardiac troponin elevation, should be suspected of myocarditis within 1-3 weeks of COVID-19 infection. When the hemodynamics change rapidly, fulminant myocarditis should be suspected. Cardiac ultrasound, myocardial biopsy, cytokine detection, cardiac magnetic resonance imaging, 18F-fluorodeoxyglucose positron emission tomography, and other examination methods can assist in the diagnosis. Although scientists and clinicians have made concerted efforts to seek treatment and prevention measures, there are no clear recommendations for the treatment of COVID-19-related myocarditis. For most cases of common myocarditis, general symptomatic and supportive treatments are used. For COVID-19-related fulminant myocarditis, it is emphasized to achieve "early identification, early diagnosis, early prediction, and early treatment" based on the "life support-based comprehensive treatment regimen." Mechanical circulatory support therapy can rest the heart, which is a cure for symptoms, and immune regulation therapy can control the inflammatory storms which is a cure for the disease. Furthermore, complications of COVID-19-related myocarditis, such as arrhythmia, thrombosis, and infection, should be actively treated. Herein, we summarized the incidence rate, manifestations, and diagnosis of COVID-19-related myocarditis and discussed in detail the treatment of COVID-19-related myocarditis, especially the treatment strategy of fulminant myocarditis.

Keywords

References

  1. Clin Immunol. 2021 Jun;227:108733 [PMID: 33895357]
  2. Rev Endocr Metab Disord. 2021 Dec;22(4):703-714 [PMID: 33025384]
  3. Pharmacol Ther. 2017 Mar;171:65-74 [PMID: 27595928]
  4. Eur Heart J. 2020 Oct 14;41(39):3863-3864 [PMID: 32710612]
  5. J Electrocardiol. 2022 Jul-Aug;73:150-152 [PMID: 33268052]
  6. Signal Transduct Target Ther. 2022 Dec 25;7(1):395 [PMID: 36566244]
  7. Elife. 2020 Oct 28;9: [PMID: 33112236]
  8. Expert Rev Anti Infect Ther. 2021 Dec;19(12):1553-1562 [PMID: 34015985]
  9. Ann Med Surg (Lond). 2021 Jul;67:102514 [PMID: 34221397]
  10. JAMA. 2020 Aug 25;324(8):782-793 [PMID: 32648899]
  11. Nat Commun. 2020 Nov 26;11(1):6013 [PMID: 33243994]
  12. Mol Biol Rep. 2022 Jan;49(1):567-576 [PMID: 34643927]
  13. Cardiovasc Res. 2020 May 1;116(6):1097-1100 [PMID: 32227090]
  14. Sci Rep. 2021 Nov 3;11(1):21632 [PMID: 34732835]
  15. Chaos Solitons Fractals. 2022 Apr;157:111954 [PMID: 35250194]
  16. Am J Cardiol. 2020 Sep 15;131:1-6 [PMID: 32732010]
  17. Nat Med. 2020 Oct;26(10):1609-1615 [PMID: 32747830]
  18. Int J Lab Hematol. 2021 Dec;43(6):1284-1290 [PMID: 33855802]
  19. AAPS J. 2021 Jan 5;23(1):14 [PMID: 33400058]
  20. Curr Heart Fail Rep. 2014 Jun;11(2):166-77 [PMID: 24723087]
  21. J Med Virol. 2022 May;94(5):1821-1824 [PMID: 34936120]
  22. Antiviral Res. 2022 Feb;198:105252 [PMID: 35085683]
  23. Front Public Health. 2022 Jul 12;10:931480 [PMID: 35903393]
  24. JACC Basic Transl Sci. 2021 Apr;6(4):331-345 [PMID: 33681537]
  25. Nat Rev Microbiol. 2021 Mar;19(3):155-170 [PMID: 33116300]
  26. Heart. 2022 Jan;108(1):46-53 [PMID: 34615668]
  27. Nat Rev Nephrol. 2021 Jan;17(1):46-64 [PMID: 33077917]
  28. Lancet. 2021 Jan 16;397(10270):220-232 [PMID: 33428867]
  29. Heart Rhythm. 2020 Sep;17(9):1463-1471 [PMID: 32387246]
  30. Eur J Heart Fail. 2020 Jun;22(6):957-966 [PMID: 32412156]
  31. Emerg Top Life Sci. 2020 Dec 11;4(4):371-378 [PMID: 33269805]
  32. J Med Virol. 2022 Apr;94(4):1738-1744 [PMID: 34905235]
  33. Intensive Care Med. 2020 May;46(5):846-848 [PMID: 32125452]
  34. J Hum Hypertens. 2021 Jan;35(1):4-11 [PMID: 32719447]
  35. Rev Med Virol. 2022 Jul;32(4):e2313 [PMID: 34755408]
  36. Expert Rev Anti Infect Ther. 2021 Mar;19(3):345-357 [PMID: 32921216]
  37. Science. 2020 Sep 4;369(6508): [PMID: 32669297]
  38. Circulation. 2023 Jan 31;147(5):364-374 [PMID: 36705028]
  39. Front Cell Infect Microbiol. 2020 Nov 25;10:587269 [PMID: 33324574]
  40. Emerg Infect Dis. 2022 Jun;28(6):1101-1109 [PMID: 35452383]
  41. Signal Transduct Target Ther. 2020 Dec 11;5(1):287 [PMID: 33303763]
  42. JAMA Cardiol. 2020 Nov 1;5(11):1281-1285 [PMID: 32730555]
  43. Am J Pathol. 2021 Aug;191(8):1374-1384 [PMID: 34033751]
  44. Nat Med. 2020 Oct;26(10):1623-1635 [PMID: 32807934]
  45. Cureus. 2021 Jan 16;13(1):e12736 [PMID: 33614338]
  46. Int J Legal Med. 2021 Nov;135(6):2347-2349 [PMID: 34486072]
  47. Biomolecules. 2021 Jul 06;11(7): [PMID: 34356617]
  48. Nat Med. 2020 Jul;26(7):1070-1076 [PMID: 32514174]
  49. Lancet. 2003 Oct 25;362(9393):1353-8 [PMID: 14585636]
  50. J Clin Invest. 2021 Dec 15;131(24): [PMID: 34710063]
  51. Cardiovasc Pathol. 2021 Jan - Feb;50:107300 [PMID: 33132119]
  52. Cardiovasc Diabetol. 2021 May 7;20(1):99 [PMID: 33962629]
  53. Intensive Care Med. 2020 Sep;46(9):1777-1778 [PMID: 32533198]
  54. Circulation. 2021 Jan 5;143(1):78-88 [PMID: 33166178]
  55. Mol Med Rep. 2021 Dec;24(6): [PMID: 34664677]
  56. Circulation. 2021 Feb 23;143(8):865-868 [PMID: 33405941]
  57. Nature. 2020 Aug;584(7821):463-469 [PMID: 32717743]
  58. Front Pharmacol. 2022 Mar 08;12:812565 [PMID: 35356629]
  59. Nature. 2022 Mar;603(7902):687-692 [PMID: 35062015]
  60. Crit Care. 2020 Dec 10;24(1):690 [PMID: 33302973]
  61. Thorax. 2021 Oct;76(10):970-979 [PMID: 33622981]
  62. Nat Rev Mol Cell Biol. 2022 Jan;23(1):3-20 [PMID: 34611326]
  63. J Cardiothorac Vasc Anesth. 2020 Jun;34(6):1591-1601 [PMID: 32127272]
  64. Sci Rep. 2022 Jul 13;12(1):11972 [PMID: 35831388]
  65. Mod Pathol. 2021 Jul;34(7):1345-1357 [PMID: 33727695]
  66. Lancet. 2015 Sep 5;386(9997):995-1007 [PMID: 26049252]
  67. Nature. 2021 Jul;595(7865):107-113 [PMID: 33915569]
  68. Circ Heart Fail. 2020 Oct;13(10):e007485 [PMID: 32844662]
  69. Clin Case Rep. 2022 Sep 02;10(9):e6185 [PMID: 36093465]
  70. Nature. 2021 Nov;599(7883):114-119 [PMID: 34488225]
  71. Chest. 2021 Mar;159(3):1182-1196 [PMID: 33217420]
  72. Cell. 2020 May 14;181(4):905-913.e7 [PMID: 32333836]
  73. Lancet. 2012 Feb 25;379(9817):738-47 [PMID: 22185868]
  74. Nat Rev Cardiol. 2021 Mar;18(3):169-193 [PMID: 33046850]
  75. Clin Res Cardiol. 2020 Dec;109(12):1549-1566 [PMID: 32803387]
  76. Nat Rev Cardiol. 2020 May;17(5):259-260 [PMID: 32139904]
  77. Am J Med. 2021 Dec;134(12):1451-1456 [PMID: 34390682]
  78. Am J Nephrol. 2021;52(3):250-260 [PMID: 33827074]
  79. Thromb Haemost. 2020 Jun;120(6):937-948 [PMID: 32316065]

Word Cloud

Created with Highcharts 10.0.0myocarditistreatmentCOVID-19-relatedcandiagnosisdiseaseCOVID-19infectionmyocardialfulminantearlymillion2SARS-CoV-2virusACE2heartinflammatorycardiacsuspectedtherapycureCoronavirus2019infectednearly600peopleresulting>6deathsmanydyingcardiovasculardiseasesSevereacuterespiratorysyndromecoronaviruscausedcombinationsurfacespikeproteinhumanangiotensin-convertingenzymereceptoradditionhighlyexpressedlungswidelydistributedmainlycellspericytesLiketypesvirusescauseinfectingtissueattributeddirectdamageuncontrolledreactionsPatientschesttightnesspalpitationabnormalelectrocardiogramtroponinelevationwithin1-3weekshemodynamicschangerapidlyCardiacultrasoundbiopsycytokinedetectionmagneticresonanceimaging18F-fluorodeoxyglucosepositronemissiontomographyexaminationmethodsassistAlthoughscientistscliniciansmadeconcertedeffortsseekpreventionmeasuresclearrecommendationscasescommongeneralsymptomaticsupportivetreatmentsusedemphasizedachieve"earlyidentificationpredictiontreatment"based"lifesupport-basedcomprehensiveregimen"MechanicalcirculatorysupportrestsymptomsimmuneregulationcontrolstormsFurthermorecomplicationsarrhythmiathrombosisactivelytreatedHereinsummarizedincidenceratemanifestationsdiscusseddetailespeciallystrategyUnderstandingmyocarditis:pathophysiologystrategiesDiagnosisMyocarditisPhysiopathologyTherapeutics

Similar Articles

Cited By